Abbreviations {#Sec1000}
=============

DICdisseminated intravascular coagulationLCHLangerhans cell histiocytosisMCVmean cell volumeTIBCtotal iron binding capacityRBCsred blood cellsWBCSwhite blood cellsSLEsystemic lupus erythematosusRArheumatoid arthritisILinterleukinTNFtumor necrosis factorPCRpolymerase chain reactionPNHparoxysmal nocturnal hemoglobinuriaSShomozygous sickle cell genesSCheterozygous sickle cell and C genesCXRchest x-rayACSacute chest syndromePKpyruvate kinaseEBVEpstein-Barr virusSDS-GCSFgranulocyte colony stimulating factorHSMhepatosplenomegalyMDSmyelodysplastic syndromeAMLacute myelogenous leukemiaASDatrial septal defectVSDventricular septal defectPDApatent ductus arteriosusTOFtetralogy of FallotCoAcoarctation of the aortaITPidiopathic thrombocytopenic purpuraHUShemolytic uremic syndromeMPVmean platelet volumeIVIgintravenous immunoglobulinDDAVPdesmopressinVWDvon Willebrand diseasePTTpartial thromboplastin timeGIgastrointestinalCMPcomplete metabolic panelESRerythrocyte sedimentation rateCBCcomplete blood countJPAjuvenile pilocytic astrocytomaCNScentral nervous systemUSultrasoundKUBkidney, ureter, and bladder x-rayU/Aurinalysis

Blood Disorders {#Sec1}
===============

Blood disorders generally fall into four categories:Red cell disordersAnemiaErythrocytosisWhite cell disordersNeutropeniaAbnormal white cellsPlatelet disordersThrombocytopeniaAbnormal plateletsCoagulation disorders

Red Cell Disorders {#Sec2}
==================

Anemia {#Sec3}
------

Incidence of anemia in childhood (Fig. [1](#Fig1){ref-type="fig"})Iron deficiency anemia (IDA), 60--70 %Hemolytic anemia, 15--20 %Hypoproliferative anemia, 10 %Maturation abnormalities, 7--8 %Fig. 1Prevalence of anemia in different age groups

Anemia in the Newborn (Fig. [2](#Fig2){ref-type="fig"}) {#Sec4}
=======================================================

Hemolysis {#Sec5}
---------

**Congenital**

HemoglobinopathiesChain defects more commonRed cell membrane defectsHereditary spherocytosisHereditary elliptocytosisHereditary stomatocytosisRed cell enzyme defectsG6PDPK

**Acquired**

NonimmuneVitamin E deficiency◦ Hemolytic anemia◦ Edema◦ ThrombocytosisInfantile pyknocytosisImmuneABORHInfectionsDICBacterialViral

**Blood loss**

PrenatalFetomaternalTwin--twin transfusionPlacentalUmbilicalPostnatalPlasma factor deficienciesPlatelets----deficiency or dysfunctionAbnormal platelet function

**Decreased red cell production**

Pure red cell aplasiaAnemia of prematurityEarlyLateIatrogenicInfectionInfiltrationCongenital leukemiaNeuroblastomaLCHOsteopetrosisFig. 2An approach to the diagnosis of anemia in the newborn infant

Approach to Diagnosis of Anemia in Older Child {#Sec6}
==============================================

Inadequate RBCs/hemoglobin (Hgb)Size of red cells (MCV) (Fig. [3](#Fig3){ref-type="fig"})Microcytic (MCV \< 70 + age) (Fig. [4](#Fig4){ref-type="fig"})Normocytic (MCV \> 70 + age and\< 100)Fig. 3Approach to anemia in older children based on MCVMacrocytic (MCV \> 100)Fig. 4Microcytic anemiaReticulocyte count

Microcytic Anemia {#Sec7}
=================

Iron Deficiency Anemia (IDA) {#Sec77}
----------------------------

Most common hematologic disease in infancy and childhood

**Etiology**

NutritionalLow birth weightRapid growthConsumption of large amount of cow's milk (\> 32 oz whole cow's milk/day)Impaired absorptionPrimary iron deficiencyMalabsorption syndromeBlood lossGastrointestinalPrimary iron deficiencyCow's milk allergy or exudative enteropathyLesions: Meckel's, vascular malformationsParasites: hookwormsGenitourinaryMenstrualHemoglobinuriaHemosiderinuriaPulmonaryGoodpasture's syndromePulmonary hemosiderosis

**Clinical Presentation**

*PallorPagophagia:* desire to eat unusual substance as ice, dirt, etc.*If Hgb level falls \< 5 g/dL*IrritabilityAnorexiaTachycardiaSystolic murmur

**Laboratory**

Low serum ferritin (depleted iron stores)Low serum iron---may fluctuateIncreased TIBC (serum transferrin)RBCs become more microcytic, hypochromic, and increased poikilocytosis as disease progresses (Fig. [5](#Fig5){ref-type="fig"})Fig. 5Peripheral blood smear example of hypochromic/microcytic anemia. Notice the variability in the sizes of red blood cells. The *arrows* point to hypochromic erythrocytes with large central hollow. (Courtesy of Dr. Nawar Hakim)Increased RBC distribution width (RDW)Normal WBCsThrombocytosis; occasionally marked (600,000--1 million/mm^3^)Low reticulocyte countMentzer index \> 13 (MCV/RBCs)

**Treatment**

Response to iron therapy is diagnostic and therapeutic.Oral administration of ferrous salts at dose of 4--6 mg/kg of elemental iron in three divided doses .Very inexpensive.Downsides; taste, Gl irritability, and constipation (more water and fiber can solve this problem).Rapid correction of anemia with transfusion may precipitate heart failure.In severely anemic children (\< 4 gm/dl) transfusions can be administered at a very slow rate (2--3 ml/kg).If there is evidence of heart failure present, a modified exchange transfusion using fresh PRBCs can be considered.Changes after treatment with iron.Within 12--24 h: irritability decreases, increased appetite.36--48 h: initial bone marrow response with erythroid hyperplasia.48--72 h: reticulocytosis, peaking at 5--7 days.1--3 months: repletion of stores.Hgb may increase by 0.5 g/dl/day.Iron therapy should be continued for at least 2 months after the Hgb normalizes to replenish iron stores.Limit *cow's* milk to less than 500 cc/day .

Anemia of Chronic Disease {#Sec8}
=========================

**Associations**

Chronic systemic diseasesChronic inflammatory process, e.g., SLE, RAChronic pyogenic infection

**Etiology**

Release of inflammatory cytokines: IL-6,IL-1,TNFHepcidin released from the liver decreases intestinal iron absorption, also block release of iron from the macrophages

**Laboratory**

Hgb concentration usually 6--9 g/dLNormal-to-low MCVOften normochromic anemia with progression to hypochromiaLow serum ironNormal-to-low TIBCElevated serum ferritin

**Treatment**

Treatment of the causeRecombinant EPO may increase the Hgb level and improve well-being in patients with cancer

Lead Poisoning {#Sec9}
==============

High serum lead levelMarkedly elevated free erythrocyte protoporphyrinBasophilic stippling of RBCsRinged sideroblasts in bone marrow

Thalassemias {#Sec10}
============

Alpha Thalassemia {#Sec11}
-----------------

Healthy individuals have 4 alpha globin genes, 2 on each chromosome 16Alpha globin production is reduced to absentSeen more frequently in those of southeast Asian and African ancestryDiagnosis: clinically or with alpha globin chain analysisExcess beta chains lead to beta 4 chains (Hemoglobin H, HbH)Excess gamma chains lead to gamma 4 chains (Hemoglobin Barts, Hb Barts)

Alpha Thalassemia Syndromes {#Sec12}
---------------------------

**Silent trait**

Deletion or dysfunction of *one* geneAsymptomatic1--2 % Hb Barts on neonatal electrophoresisNormal Hgb electrophoresis

**Alpha thalassemia trait**

Deletion or dysfunction of two genesMild hypochromic microcytic anemia3--10 % Hb Barts on neonatal electrophoresisLaboratoryMentzer Index \< 13Hgb \> 9 g/dlNormal Hgb electrophoresisOften misdiagnosed as IDA

**Hemoglobin H disease**

Deletion of three genesMild-to-moderate hypochromic microcytic anemiaSplenomegalyJaundiceCholelithiasis (pigment stones)Anemia exaggerated by infection, pregnancy, exposure to oxidizing drugs\> 25 % Hgb Barts on neonatal electrophoresis

**Alpha thalassemia major**

Deletion of four genesFetal hydrops-fatal diseasePredominant Hb Barts

Beta Thalassemia {#Sec13}
----------------

Healthy individuals have 2 beta globin genes, 1 on each chromosome 11Beta globin production is reduced to absentMultiple possible genetic mutations or deletionsMore clinical overlapSeen more frequently in those of Mediterranean, southeast Asian ancestryAlso seen in African Americans but generally have a milder courseRelative alpha chain excess leads to shortened red cell survival and variable splenic sequestrationDiagnosed by hemoglobin electrophoresis or beta globin chain analysisCannot be diagnosed by electrophoresis in the neonateIron, folate, and B12 must be repleted to have an accurate hemoglobin electrophoresis

Beta Thalassemia Syndromes {#Sec14}
--------------------------

Beta thalassemia minor---silent or near silent trait (heterozygous β0 or β +)AsymptomaticSmear can be normalOccasional microcytosis, hypochromia, target cells, basophilic stipplingOften normal indices or decreased MCVNormal to slightly elevated HgbA2 on electrophoresis

**Thalassemia intermedia**

More symptomatic than thalassemia traitRefers to a clinical phenotype with diverse genetic explanationsLaboratoryMicrocytosis, hypochromia, target cells, and basophilic stippling on smearMentzer Index \< 13Hgb usually between 7 and 10 g/dlElevated HgbA2 and HgbF on electrophoresis

**Thalassemia major (Cooley's anemia)**

Variable reduction of beta globin gene productionHomozygous or double heterozygous forms (β0, β + variants)Excess alpha globin chains result in increased destruction of RBCs and ineffective erythropoiesisShortened red cell life span and splenic trappingClinical presentationGeneral◦ Dependent on amount of HgbF◦ Severe anemia with increased iron absorption and subsequent toxicity◦ Pallor, jaundice, fatigue◦ HepatosplenomegalySkeletal◦ Typical facial features with maxillary hyperplasia, flat nasal bridge, frontal bossing◦ Pathological bone fracturesEndocrine dysfunction◦ Hypothyroidism◦ Hypoparathyroidism◦ Diabetes mellitusCardiovascular◦ Congestive heart failure◦ Cardiac arrhythmiasLaboratorySevere anemiaFew reticulocytes \< 8 % compared to degree of anemiaMicrocytosis with no normal appearing RBCs on the smearNumerous nucleated RBCsTarget cellsMentzer index(MCV/RBCs) is \< 9Indirect (unconjugated) bilirubin is elevatedTreatmentChronic transfusion therapyBefore chronic transfusion is initiated diagnosis of beta thalassemia must be confirmed firstDeferoxamine for iron chelationNewer chelating agent, deferasirox (Exjade, Novartis), is oral and more tolerable but long term data still being accumulated

Other Hemoglobinopathies {#Sec15}
------------------------

Hemoglobin EHemoglobin LeporeHemoglobin Koln

Rare Disorders {#Sec16}
--------------

Sideroblastic anemiaMay be microcyticIneffective erythropoiesis caused by iron deposition in erythroblastsMild-to-moderate hemolysisRinged sideroblasts in bone marrowProtein calorie malnutrition-microcytosis without IDAMetabolic abnormalities of iron absorption and metabolism

Macrocytic Anemia (MCV \> 100 in Child Older than 2) {#Sec17}
====================================================

Folic Acid Deficiency {#Sec18}
---------------------

**Etiology**

NutritionalSources---leaves; vegetable; fruits; animal organs, for example, liver and kidneysBody stores for folic acid is limited 2--3 months on folate-free dietInadequate intake---during pregnancy, growth in children, and hemolytic anemiaGoat milk consumptionDecreased folic acid absorption---removal of ileum or IBDAnticonvulsant medication, for example, phenytoin, primidoneCongenital dihydrofolate reductase deficiencyDrug-induced abnormal metabolism---Methotrexate

**Clinical presentation**

Megaloblastic anemiaIrritabilityInadequate weight gainChronic diarrheaHemorrhage from thrombocytopenia in severe cases

**Laboratory**

Macrocytic anemia (MCV\> 100; Fig. [6](#Fig6){ref-type="fig"})Fig. 6Red cells are usually approximately the size of a small lymphocyte nucleus (*arrow*). In this case the red cells are slightly larger than the lymphocyte nucleus on average. Macrocytic anemia is most often a result of folate or vitamin B12 deficiencyMegaloblastic changes including hypersegmented neutrophils (\> 5 lobes)Elevated LDHHypercellular bone marrow

**Treatment**

Rule out B12 deficiency before starting folic acid therapyFolic acid 0.5--1 mg/day IV or oralHematologic response can occur within 72 h (diagnostic test as well)Treatment continued for only 3--4 weeksMaintenance dose is 0.2 mg daily

Vitamin B12 Deficiency {#Sec19}
----------------------

Vitamin B12 stores last for 3--5 yearsSources---animal products

**Etiology**

Inadequate B12 intake (strict vegan)Exclusively breast fed and maternal vegan dietRemoval of terminal ileumInflammatory bowel diseaseFish tapeworm (Diphylobothrium latum)Absence of Vitamin B12 transport protein and stomach intrinsic factor (IF)

**Clinical presentation**

WeaknessFatigueFailure to thriveIrritabilityPallorGlossitisVomitingDiarrheaIcterusNeurologic symptomsParesthesiasDevelopmental regressionNeuropsychiatric changes

**Laboratory**

Macrocytic anemia (MCV \> 100; see Fig. [6](#Fig6){ref-type="fig"})Megaloblastic changes including hypersegmented neutrophils (\> 5 lobes)Elevated LDHNormal iron and folic acid levelsIncreased methylmalonic acid in urineIncreased homocysteineLow reticulocyte count for degree of anemiaAntiparietal cell antibody positive in pernicious anemiaLess than 10 % of cases present under age 40Classic Schilling test is no longer regarded as the diagnostic test

**Treatment**

Parenteral administration of Vitamin B12 1 mg dailyWith neurologic involvement continue for minimum of 2 weeksReticulocytosis in 2--4 days unless concurrent inflammatory diseaseMaintenance of monthly IM Vitamin B12

Pearson Marrow--Pancreas Syndrome {#Sec20}
=================================

Variant of sideroblastic anemia

**Clinical presentation**

Macrocytic anemia in neonatal periodElevated level of alpha fetoproteinNeutropeniaThrombocytopeniaFailure to thrive*Pancreatic fibrosis*Insulin dependent diabetes mellitusExocrine pancreatic deficiencyMuscle and neurologic impairment

**Laboratory**

Bone marrowRinged sideroblastVacuolated erythroblast and myeloblastOften confused with Diamond--Blackfan anemia and transient erythroblastopenia of childhood

Diamond--Blackfan Anemia (Congenital Hypoplastic Anemia) {#Sec21}
========================================================

Primary defect in the erythroid progenitors

**Clinical presentation**

Profound anemia manifested by 2--6 months of ageMore than 50 % have congenital anomaliesShort statureCraniofacial dysmorphism (snub nose, wide-set eyes, thick upper lip)*Triphalangeal thumbs*Bifid, subluxed, absent, or supernumerary thumbs

**Laboratory**

Macrocytic RBCs with no hypersegmentation of neutrophilsNormal B12 and folateIncreased adenosine deaminase activity in most patientsDecreased RBCs precursor in bone marrowElevated serum ironNormal bone marrow chromosomal studiesNormal to low reticulocyte countNegative PCR for Parvovirus B19

**Treatment**

SteroidsIron chelating agents (if transfusion dependent)Stem cell transplantation for non respondents to corticosteroids, and after several years of RBC transfusions

**Prognosis**

Median survival \> 40 years

Normocytic Anemia (MCV \> 70 + Age and \< 100 in Child Older Than 2; Fig. [7](#Fig7){ref-type="fig"}) {#Sec22}
=====================================================================================================

Fig. 7Approach to normocytic anemia

Transient Erythroblastopenia Childhood {#Sec23}
======================================

**Background**

Most common acquired red cell aplasia in childhoodMore common than Diamond--Blackfan anemia (congenital hypoplastic anemia)

**Etiology**

Transient suppression of RBC productionOften noted after a viral infectionNo evidence of Parvovirus B19

**Clinical presentation**

Age---3 months to 3 years of age, most \> 12 monthsMore common in males

**Laboratory**

MCV normal for ageHemoglobin can be as low as 2.2 g/dlReticulocytes decreasedBone marrow biopsy rarely needed but erythroid suppression seenNormal adenosine deaminase (ADA)

**Treatment**

ReassuranceRecover within 2--3 monthsOccasionally transfusion is necessary

Hereditary Spherocytosis {#Sec24}
========================

**Background**

Autosomal-dominant inheritanceLess frequently can be autosomal recessive25 % of patients have no family historyMost common molecular defects are in spectrin or ankyrin, major components of the RBC cytoskeleton

**Clinical presentation**

May be asymptomatic into adulthoodAnemiaHyperbilirubinemia sufficient to require exchange transfusion in newborn periodPallorJaundiceFatigueExercise intoleranceSplenomegalyPigment gallstones may form as early as 4--5 years of ageSusceptible to aplastic crisis as a result of parvovirus B19 infectionsErythroid marrow failure may result rapidly in profound anemia HCT \< 10 %, high cardiac output failure, hypoxia, cardiovascular collapse, and death; platelet may also fall

**Laboratory**

ReticulocytosisIndirect hyperbilirubinemiaHigh LDHLow haptoglobinNormal MCVElevated MCHCHigh percentage of spherocytes on smear (Fig. [8](#Fig8){ref-type="fig"})Fig. 8Red cells should be similar in size to the small lymphocyte nucleus (*center*). In hereditary spherocytosis the red cells are small and hyperchromatic, lacking central pallor (40 ×). *Red arrows* point out a few of the examples in this fieldCan be confirmed with osmotic fragility test or flow cytometry

**Treatment**

Folic acid 1 mg po daily to prevent deficiency and the resultant decrease in erythropoiesisSplenectomy indications:Hgb \< 10 g/dlReticulocytosisAplastic crisisPoor growthCardiomegalySome do not recommend splenectomy in patients with hemoglobin \> 10 g/dl and reticulocytes \< 10 %Vaccination for encapsulated organism *Haemophilus influenza*, meningococcus, pneumococcus should be given before splenectomy, then prophylactic penicillin V 125 mg BID \< 5 years and 250 BID for \> 5 yearsPartial splenectomy is useful in children \< 5 years

Hereditary Elliptocytosis {#Sec25}
=========================

Less common than hereditary spherocytosis (HS)

**Clinical presentation**

Presentation same as in HS

**Laboratory**

Red blood cells shows various degree of elongation, may be rod shapedOther abnormal shapes may be present microcytosis, spherocytes, poikilocytosis

**Treatment**

No treatment necessary unless hemolysis presentOtherwise same as in HS

Paroxysmal Nocturnal Hemoglobinuria {#Sec26}
===================================

**Background**

Most often caused by an acquired (rather than inherited) intrinsic defect in the cell membraneDeficient membrane associated protein include decay-accelerating factor, C8-binding protein

**Clinical presentation**

Nocturnal and morning hemoglobinuriaThrombosis and thromboembolic phenomena is a very serious complicationAplastic anemia may precede the episodes of PNH

**Laboratory**

Red blood cells shows various degree of elongation; may be rod shapedEvidence of hemolysis---elevated LDH, elevated bilirubin, low haptoglobinNegative direct antiglobulin testFlow cytometry for CD55 and CD59Positive results on acidified serum hemolysis Ham test, or sucrose lysis test (historical)Markedly decreased acetylcholinesterase activity and decay accelerating factor is found

**Treatment**

AcuteTransfusion to suppress production of PNH cellsGlucocorticoids 2 mg/kg/24 h (controversial)ChronicEculizumab prevents complement binding and decreases hemolysisWarfarin to prevent thrombotic complicationsMay need supplemental iron to offset losses from hemoglobinuria

Sickle Cell Disease (SCD) {#Sec27}
-------------------------

**Background**

Hemoglobin S is the result of a mutation resulting in a substitution of valine for glutamic acid at sixth position in beta globin chainAutosomal recessive inheritance

**Clinical presentation**

Usually diagnosed on neonatal screenManifestations of clinical symptoms can be as early as 6 months of ageCrisesSplenic sequestrationPain crisisAplastic crisisParvovirus B19 frequent cause of aplastic crisesInfectionsBacterial sepsis is the greatest cause of morbidity and mortalityBacterial infection by encapsulated organisms is the most common at all agesFunctional asplenia as early as 6 months, by age 5 in most children

**Laboratory**

AnemiaSickle cells on smear (Fig. [9](#Fig9){ref-type="fig"})Fig. 9Peripheral smear (40 ×) from a patient with sickle cell disease showing sickle cells (*black arrows*), target cells (*arrowhead*), and a Howell--Joley body (*red arrow*)Positive sickle prepHemoglobin electrophoresis---SS, SC, SD

**Management**

FeverMedical emergency due to high risk of severe bacterial infection and high fatalityParenteral IV third generation cephalosporin (Cefotaxime)Penicillin VK oral prophylaxis until 5 years of age125 mg PO BID until 3 years250 mg PO BID until 5 yearsContinue past 2 years of age if history of infection with encapsulated organismOsteomyelitis---frequently staph or salmonella

**Pain crisis**

HydroxyureaIncreases level of hemoglobin F and total hemoglobinDecreases the pain crises by 50 %Side effect is myelosuppression, but reversibleIf begun in infancy may preserve the splenic function, improve the growth, and decrease ACSInitial dose is 15--20 mg/kg increase gradually by 2.5--5 mg/kg up to max of 35 mg/kg/dayMonitor for toxicity

**Aplastic crisis**

RBC lifespan is between 10 and 20 days in patient with SCDCessation of RBC production for 10--14 days can lead to profound anemiaClinical presentationPallorFatigueDecreased activityPoor feedingAltered mentationLaboratorySevere anemiaReticulocytopeniaOccasional thrombocytopeniaManagementTransfusion support as needed until reticulocyte recovery has occurred.Dactylitis (hand--foot disease)Often the first manifestation of pain in childrenOccurs in 50 % of children by 2 years of ageUnilateral can be confused with osteomyelitisTreatment◦ Pain medications (e.g.,acetaminophen with co-deine)

**Splenic sequestration**

Etiology unknown30 % of children with sickle cell anemia have episodes of significant sequestrationClinical presentationIncrease in size of spleenEvidence of hypovolemiaDecline in hemoglobin of at least 2 g/dl from the base lineTreatmentMaintenance of hemodynamic stabilityIsotonic fluidBlood transfusionPrognosisRepeat sequestration is very commonParents should be taught how to palpate the spleen

**Vaso-occlusive crisis**

Disruption of blood flow in microvasculature by sickle cellsRisk factors exposure to cold, hypoxia, and acidosisClinical presentationPain which can affect any part of the bodyPain most often in chest, back, abdomen, and extremitiesManagementPain medicationsAcetaminophen up to IV morphine depending on the severityIV hydration does not relieve the painBlood transfusion does not prevent or relieve the painConcern about opioids dependency must not be a reason not treat a child with pain

**Priapism**

Penile erection lasts \> 30 minPain medicationSitz bathPenile erection lasts \> 4 hMay result in sexual dysfunctionAspiration of blood from corpora cavernosaFollowed by irrigation with diluted epinephrine will cause immediate relief

**Neurological complications**

11--20 % will have either overt or silent strokeOvert stroke means presence of focal neurological deficit \> 24 h and or cerebral infarct by T2-weighted MRISilent stroke means absence of focal neurological lesions \> 24 h with cerebral infarct on T2-weighted MRIClinical presentationHeadacheSeizuresCerebral venous thrombosisReversible posterior leukoencephalopathy syndrome (RPLS)TreatmentOxygen to maintain saturation \> 96 %Transfusion within 1 h to increase Hgb level to max of 11 g/dLCT to exclude cerebral hemorrhagePrimary prevention of strokeTCD (transcranial Doppler) to measure blood velocityIf blood velocity is \> 200 cm/s prophylactic transfusion is indicated to decrease the Hgb S to \< 30 %Can start as early as 2--3 years of ageSecondary preventionTransfusion therapy after initial strokeMaintain the Hgb S \< 30 %Complications:20 % have second stroke in the first year after first strokeIron overload (200 mg of iron/unit RBCs):Iron-chelating agentsPhlebotomyErythrocytapheresis (expensive and complicated)

**Acute chest syndrome**

Clinical presentationFeverRespiratory distressChest painNew radiodensity on CXRAll patients with fever should have CXR even in absence of respiratory symptomsTreatmentOxygenSimple exchange transfusion indications:◦ Decreasing oxygen saturation◦ Increasing work of breathing◦ Rapid change in respiratory effortMost common episode preceding ACS is pain crisis treated with opioids, especially morphineOverlap between pneumonia and ACS requires use of macrolide and third-generation cephalosporinMost common organism in ACS: *S. pneumoniae,*Mycopl *asma, Chlamydia pneumoniae*Pulmonary hypertensionPH is a major risk of death in adult with sickle cell anemia

**Renal disease**

Gross hematuriaPapillary necrosisNephritic syndromeRenal infarctsPyelonephritisRenal medullary necrosisTreatmentACE inhibitors beneficial for patients with proteinuria

**General considerations**

High risk of academic failure, poor high school graduation rate1/3 of children have cerebral infarctsOther complication of sickle cell anemiaDelayed pubertyVascular necrosis of femoral headRetinopathySurgical procedures---complications include pain and ACS post operativelyBlood transfusion before surgery to keep the hemoglobin approximately 10 g/dl

Methemoglobinemia (congenital or acquired) {#Sec28}
------------------------------------------

Decrease ability to release o2 to tissuesMethemoglobin of 15 % associated with visible cyanosisMethemoglobin of 70 % is lethalMethemoglobin colors the blood brownExposure to 100 % oxygen will change the colorTriggersRotavirus infectionGastroenteritisWater high nitritesAniline teeth gelTreatment: methylene blue

Pyruvate Kinase Deficiency {#Sec29}
--------------------------

**Background**

Active enzyme in Embden--Meyerhof pathwayDeficiency leads to defective red cell glycolysis and decrease ATP productionRed cells are rigid and deformed, metabolically and physically vulnerable with decreased red cell survival

**Clinical presentation**

Varies from severe neonatal hemolytic anemia to mild well compensated hemolysisSevere jaundice and anemia and can occur during neonatal periodSplenomegalyAplastic crisis with parvovirus B19 infection

**Laboratory**

Reduced RBC PK enzyme levelElevated reticulocyte countSmear with polychromatophilia, macrocytosis, ovalocytes, acanthocytes, or pyknocytes

**Treatment**

Exchange transfusion may be indicated for hyperbilirubinemia in newbornBlood transfusion as necessaryFolic acid supplementationSplenectomy should be performed if frequent transfusion after age 5--6 years

Glucose-6-Phosphate Dehydrogenase {#Sec30}
---------------------------------

**Pathophysiology**

First enzyme in the pentose phosphate pathway of glucose metabolismActivity falls rapidly as red cell agesDecreased glucose metabolism with impaired elimination of oxidants and subsequent loss of red cell membrane integritySeverity of hemolysis depends on the quantity and type of G6PD deficiency and nature of hemolytic agent (usually an oxidation mediator) (Table [1](#Tab1){ref-type="table"})Table 1WHO classification of G6PD deficiencyClassLevel of deficiencyEnzyme activityPrevalenceISevere\< 10 % enzyme activity; chronic non-spherocytic hemolytic anemia in the presence of normal erythrocyte functionUncommon; occurs across all populationIISevere\< 10 % enzyme activity with intermittent hemolysisVaries; more common in Asian and Mediterranean populationsIIIModerate10--60 % enzyme activityHemolysis with stressor only10 % of black males in USAIVMild to none60--150 % enzyme activityNo clinic sequelaeRareVNone\> 150 % enzyme activityNo clinic sequelaeRare

**Genetics**

X-linked recessiveVariable intermediate expression shown by heterozygous femalesMore common in African American and Mediterranean ancestry

**Clinical presentation: episodes of hemolysis produced by:**

DrugsAntioxidant drugs include:◦ Aspirin◦ Sulfonamides◦ AntimalarialsUsually 24--48 h after exposureHemoglobin usually normal between episodesOccasionally need additional stress of infection or neonatal stateFava beansAcute life-threatening, often leading to acute renal failureAssociated with Mediterranean and Canton varietiesBlood transfusions usually requiredInfectionNeonatal jaundiceAssociated with Mediterranean and Canton varietiesOccasional exposure to naphthalene, aniline dyes, marking ink, or other drugInfants may present with pallor, jaundice, dark urineJaundice may be hepatic in originOften no known exposure to drugsChronic nonspherocytic hemolytic anemiaMainly in northern EuropeansReticulocytosisIncreased autohemolysis with only partial correction by glucoseSlight jaundiceMild splenomegaly

**Laboratory**

AnemiaHeinz bodies seen in unstained red blood cells due to hemoglobin precipitationDiagnosis demonstrated by reduced G6PD activity in RBCs should be few weeks after the hemolytic episode

**Treatment**

Avoidance of agentsTransfusion as neededFolic acid supplementationChronic nonspherocytic hemolytic anemiaConsider chronic transfusion to keep Hgb at approximately 8 g/dlIron chelation as neededSplenectomySevere chronic anemiaHypersplenismSplenomegaly with physical impediment

Other Enzyme Deficiencies {#Sec31}
-------------------------

Hexokinase deficiencyGlucose phosphate isomerase deficiencyAldolase deficiencyDiphosphoglycerate deficiencyAdenosine triphosphate deficiencyEnloase deficiencyPhosphofructokinase deficiencyMyopathyAssociated with type VII glycogen storage diseaseCommon in Ashkenazi JewsTriosephosphate isomerase deficiencyCardiac anomaliesRecurrent infectionsProgressive neuromuscular disease with generalized spasticityPhosphoglyercate kinase deficiencyFirst ATP generating enzymeSex-linked recessiveIntellectual disability (ID)SeizuresBehavioral disorders

Autoimmune Hemolytic Anemia {#Sec32}
===========================

**Etiology**

Antibodies against antigens on RBCs surfaceIgG against Rh complex is the most common in childrenIgM cold antibodies usually associated with infections, for example, *Mycoplasma* and *EBV*

**Clinical presentation**

PallorJaundicePyrexiaHemoglobinuriaSplenomegaly

**Laboratory**

Profound anemiaReticulocytosisPositive direct antiglobulin (Coombs) testPolychromasiaSpherocytosisHigh cold agglutinin titre

**Treatment**

Supportive treatment for mild casesCorticosteroids for IgG mediated diseaseBlood transfusion (blood unit with the least reaction by Coomb's technique)IVIgSplenectomy in persistent cases

**Prognosis of acute form**

Response to glucocorticoidsLow mortality rateFull recovery

Hemolytic Anemia Secondary to Extracellular Factors {#Sec33}
===================================================

Mechanical injuryHUSKasabach-Merrit syndrome: hemangioma and thrombocytopeniaThermal injuryRenal diseaseLiver diseaseChange in cholesterol to phosphlipid level which affects the membrane of RBCToxins and venom*Streptococcus, haemophilus influenzae, staphylococcus and clostridium* infectionCobras, rattlesnakes, have phospholipids in their venom---cause spherocytic hemolysis

Erythrocytosis {#Sec34}
--------------

**Definition**

RBCs 25 % \> upper normal value

**Clinical presentation**

Hypertension, headache , shortness breath, neurologic symptoms, thrombocytosis may cause hemorrhage and thrombosis

**Primary (polycythemia vera)**

Major criteriaIncreased red cell massArterial oxygen saturation \> 92 %Palpable spleenMinor criteriaPlatelet count \> 400,000Leukocytosis \> 12,000Increased leukocyte alkaline phosphataseIncreased vitamin B12 \> 900 pg/ml, binding capacity \> 2200 pg/ml

**Secondary**

Increase HCT \> 65 %Clinical presentationHyperviscosity, headache, hypertensionEtiologyFamilial◦ HemoglobinopathyHypoxia◦ Altitude◦ Cardiac disease◦ Lung disease◦ Central hypoventilationHormonal◦ Adrenal◦ AnabolicRenal◦ Tumor/cysts◦ Renal artery stenosis◦ HydronephrosisLiver◦ Dysfunction◦ HepatomaMetabolic◦ 2,3 diphosphoglycerate deficiencyNeonatal◦ Normal intrauterine environment◦ Twin-Twin transfusion◦ Diabetic mother◦ IUGR◦ Trisomies◦ Congenital adrenal hyperplasia◦ Thyrotoxicosis

**Treatment**

Periodic phlebotomy for hematocrit \> 65--70 % or hemoglobin \> 23 g/dl

Fanconi Anemia {#Sec35}
--------------

**Genetics**

Autosomal recessive

**Clinical presentation**

Skin abnormalities in 65 % of casesHyperpigmentation of the trunk and intertriginous areas, café-au-lait spots, vitiligoShort stature---60 %Upper limb anomalies---50 %*Absent thumbs*Triphalangeal thumbsCongenital hip dysplasiaMale genitalia---40 %Underdeveloped penisUndescended testesHypogonadismFemale genitaliaMalformation of vagina, uterusFacial anomaliesMicrocephaly , small eyes, epicanthal folds, abnormal shape ears, or absent earsIntellectual disability (ID)---10 %Kidney abnormalitiesHorseshoe kidney, absent, or duplicate kidney

**Laboratory**

Macrocytic anemiaVariable progression to full-blown pancytopenia due to aplasia

**Complications**

Acute leukemiaCarcinoma of head and neck, and upper esophagus

Shwachman--Diamond Syndrome {#Sec36}
---------------------------

Rarest form of pancytopenia

**Genetics**

Autosomal recessive

**Clinical presentation**

Failure to thriveExocrine pancreatic insufficiency---50 %Fat malabsorption---absence of steatorrhea does not exclude SDSSkeletal abnormalitiesShort stature---Metaphyseal chondrodysplasiaAbnormal digits---syndactyly, clinodactyly, or supernumerary metatarsalsAbnormal faciesBifid uvula, short, or cleft palateDental dysplasiaHypertelorismMicrocephalyRetinitis pigmentosaRecurrent bacterial infections

**Laboratory**

Abnormal pancreatic enzymes and steatorrheaNeutropeniaBone marrow showing myeloid hypoplasiaPancytopenia---60 %

**Diagnosis**

Mutation analysis for SBDS is definitive in 90 %

**Complications ---increase with age, usually after 10 years of age**

Aplastic anemiaMyelodysplastic syndromeAcute myelogenous leukemia

**Treatment**

Androgen with low-dose prednisone

White Cell Disorders {#Sec37}
====================

Neutropenia {#Sec38}
-----------

**Acute**

Viral infectionEpstein--Barr virusRespiratory syncytial virusInfluenza A and BHepatitisHuman herpesvirus 6 (HHV 6) infectionsBacterial infectionHypersplenismDrug-induced---recovery after medication cessationAntimicrobials---sulfonamides, penicillinAntirheumatics---gold, phenylbutazone, penicillamineAnticonvulsants---phenothiazineAnalgesic and anti-inflammatory---ibuprofen

**Chronic**

Cyclic neutropeniaClinical presentation◦ Approximately 21-day cycles with changing neutrophil counts with neutropenia spanning 3--6 days◦ Nadir may be in severe range◦ Fever and oral ulceration often during nadir◦ Gingivitis, pharyngitis, skin infections during nadir◦ Occasionally more serious infections---pneumonia, necrotizing enterocolitis with peritonitis, and *Escherichia coli* or *Clostridium* sepsis.◦ Count may be recovering when brought to medical attentionLaboratory◦ Counts 2--3/week for 6 weeksTreatment◦ Prophylactic GCSF during nadir in some cases◦ Immediate attention with feversChronic benign neutropeniaNo specific abnormality foundNo serious infectionsNo treatment necessary except attention for fevers

**Congenital**

Kostmann syndrome (severe congenital neutropenia)Autosomal recessiveClinical presentation◦ Mouth ulcers◦ Gingivitis◦ Otitis media◦ Cellulitis◦ Respiratory infections◦ Skin infections and abscesses---most common◦ Pneumonia and deep tissue abscesses---often life threatening◦ Mild HSM◦ Progress to MDS/AMLTreatment◦ GCSF◦ Stem cell transplant for MDS/AMLCartilage hair hypoplasiaChédiak--Higashi syndromeFanconi anemia

**Immune**

Autoimmune neutropeniaNeonatal alloimmune neutropeniaDysgammaglobulinemiaHyper IgM syndromeHIVPNH

**Nutritional**

B12 and folic acid deficiency---ineffective erythropoiesis with neutropenia

**Bone marrow infiltration**

MalignancyMDSLymphoproliferative disorders

Platelet Disorders (Fig. [10](#Fig10){ref-type="fig"}) {#Sec39}
======================================================

Fig. 10Approach to platelet disorders

Thrombocytopenia {#Sec40}
----------------

Decreased Production {#Sec41}
--------------------

### Amegakaryocytic Thrombocytopenia {#Sec42}

**Genetics**

Autosomal recessive

**Clinical presentation**

Rash, bruising, or bleeding at birthMost common anomalies:Neurologic---cerebellar and cerebral atrophy are frequentCardiac findings---ASD, VSD, PDA, TOF, CoAOther anomaliesAbnormal hips, feet, kidney, eye, and palate malformation

**Diagnosis**

Initially absent megakaryocytes then pancytopeniaIf beyond neonatal periods, bone marrow aspirate, and biopsy will confirm the diagnosis

Thrombocytopenia Absent Radius Syndrome (TARS) {#Sec43}
----------------------------------------------

**Clinical presentation**

ThrombocytopeniaAbsent radiusCongenital heart disease---TOF, ASD, VSDOthersEosinophiliaLeukemoid reactionIntellectual disability (ID)

Increased Destruction {#Sec44}
---------------------

Normal to increased megakaryocytes in bone marrowPlatelet destructionImmune◦ ITP◦ DrugsNon-Immune◦ TTP◦ HUS◦ DIC◦ Infection◦ Cardiac

### Idiopathic Thrombocytopenic Purpura (ITP) {#Sec45}

**Etiology**

Antiplatelet antibodyOften a few weeks after infection

**Clinical presentation**

Petechiae, ecchymoses, epistaxisVariable symptoms, but usually healthy appearing child

**Laboratory**

ThrombocytopeniaNormal to increased size of platelets (MPV)Normal RBCs and WBCs

**Treatment**

ObservationIVIgSteroidsWinRhoPlatelet transfusion is contraindicated unless life threatening bleeding is presentSplenectomy if \> 4 years of age with severe ITP longer than 1 yearNeonatal immune thrombocytopeniasAutoimmuneAlloimmuneErythroblastosis fetalisSecondaryViralBacterialDrug inducedPosttransfusion purpuraSLEHyperthyroidismLymphoproliferative disorders

### Hemolytic uremic syndrome {#Sec46}

**Background**

Non-immuneMicroangiopathic hemolytic anemia*E. coli* O157:H7 is a very common cause*Shigella dysenteriae* type I is a another cause

**Clinical presentation**

Usually children between 4 months and 2 yearsInfection with gastrointestinal symptoms---vomiting and often bloody diarrheaDevelopment of oliguria, hypertension, renal failure

**Laboratory**

ThrombocytopeniaMicroangiopathic hemolytic anemiaHelmet cells, schistocytes, burr cells, spherocytesElevated BUN and creatinineReduced large multimers of von Willebrand factor (VWF)Decreased immunoglobulins in some patientsDecreased prostaglandin 12 (PG12) in some patients

**Treatment**

Aggressive management of renal failureCorrection of anemia with transfusionAvoid platelet transfusion if possible

### Thrombotic Thrombocytopenic Purpura (TTP) {#Sec47}

**Background**

NonimmuneMicroangiopathic hemolytic anemia

**Etiology**

IdiopathicAcute◦ Autoantibody, ADAMTS13 IgG inhibitorChronic◦ ADAMTS13 mutation◦ Mutation of HF geneSporadic◦ Gene mutations may be less severeSecondaryAutoimmune diseaseMalignancyInfectionDrugsStem cell transplantationBacterial endocarditis

**Clinical presentation**

FeverHeadacheMalaiseAbdominal/chest painArthralgia/myalgiaNausea/vomitingPallorPurpuraJaundiceFluctuating neurologic signs and symptomsProgressive renal failure

**Laboratory**

ThrombocytopeniaDICBlood smear with polychromasia, basophilic stippling, schistocytes, microspherocytes, and nucleated RBCs (Fig. [11](#Fig11){ref-type="fig"})Fig. 11Peripheral smear (40 ×) from a patient with hemolytic anemia showing a schistocyte (*arrow*) as well as fragmented cells (*arrowheads*). Note the presence of nucleated red cells (*red arrows*)Elevated VWF antigenReduced haptoglobinHemoglobinuria and hemosiderinuriaIncreased unconjugated bilirubinIncreased LDHWidespread hyaline microthrombi in the microvasculature in biopsy specimensOther disorders with consumption thrombocytopeniaDICVirus associated hemophagocytic syndromeHemangioma (Kasabach--Merritt syndrome)Cyanotic heart disease

Abnormal Platelets {#Sec48}
==================

Wiskott--Aldrich Syndrome {#Sec49}
-------------------------

ThrombocytopeniaTiny plateletEczemaRecurrent infection

Bernard--Soulier Syndrome {#Sec50}
-------------------------

Absence or deficiency of VWF receptors on the platelet membraneMarkedly prolonged bleeding time

Glanzmann's Thrombasthenia {#Sec51}
--------------------------

Severe platelet dysfunction that yield prolonged bleeding timeNormal platelet countAggregation studies show abnormal or absent aggregationProlonged bleeding time

Coagulation Disorders {#Sec52}
=====================

Hemophilia {#Sec53}
----------

X-linked recessiveFactor VIII (hemophilia A)---85 %Factor IX (hemophilia B)---10--15 %Bleeding may start from birth or even fetus

**Clinical presentation**

Easy bruisingIntramuscular (deep) hematomas---localized pain and swellingHemarthrosesHallmark of hemophiliaAnkle most commonKnee and elbow increasing frequency with age

**Laboratory**

PTT is usually 2--3 times upper limit of normalPT, bleeding time, platelet count normalSpecific assay for factor VIII or IX will confirm the diagnosis

**Classifications**

Severe hemophilia \< 1 %Moderate hemophilia 1--5 %Mild hemophilia \> 5 %

**Treatment**

Factor replacementMild to moderate bleeding---raise factor to 35--50 %Severe or life threatening hemorrhage---raise level to 100 %Lifelong prophylaxis usually started with first joint hemorrhageDDAVP may be sufficient in mild forms of hemophiliaAvoidance of high risk behavior

**Complications**

Severe hemorrhageArthropathy

Von Willebrand Disease {#Sec54}
----------------------

**Etiology**

VWF is a carrier protein for factor VIIIVWF stored in platelets and endothelial cellVWF adheres to exposed the subendothelial matrix after vascular damage causing platelets to adhere via glycoprotein IB receptors on the VWF

**Clinical presentation**

VWD usually have symptoms of mucocutaneous hemorrhageExcessive bruising, epistaxis, menorrhagia, post-operative bleeding (e.g., tonsillectomy, wisdom teeth extraction)Females more commonly diagnosed than males secondary to menorrhagiaAny menstruating female with iron deficiency, should have a detailed history of bruising and other bleeding symptomsStress doubles or triples level of VWF

**Laboratory**

No single assay to rule out or diagnose VWFBleeding time or PFAPTT---often prolonged but frequently normal in type 1 VWDVWF antigenVWF Ristocetin cofactor activityPlasma factor VIII activityVWF multimersPlatelet count

**Treatment**

Based on subtype and trial of DDAVPType 1 usually treated with DDAVPDDAVP 0.3 microgram/kg increases the level of VWF and factor VIII 3--5 foldType 2B and 3 primarily treated with FVIII:VWF concentratesPlatelet type treated with platelet transfusions

Disseminated Intravenous Coagulopathy {#Sec55}
-------------------------------------

**Etiology**

Widespread intravascular consumption of platelets and plasma clotting factors and deposition of fibrin

**Clinical presentation**

Bleeding (e.g., from venipuncture sites)Petechiae, ecchymosesClot formationAssociated conditionsTissue injury◦ Trauma, especially cranial◦ Burns◦ Venom◦ Malignancy◦ Obstetric emergenciesEndothelial cell injury or abnormal vascular surfaces◦ Infection/sepsis◦ Immune complexes◦ Eclampsia◦ Oral contraceptives◦ Giant hemangioma◦ Respiratory distress syndrome (ARDS)◦ MalignancyPlatelet, leukocyte, or red cell injury◦ Incompatible blood transfusion◦ Infection◦ Allograft rejection◦ Hemolytic syndromes◦ Drug hypersensitivity◦ Malignancy

**Laboratory**

Prolonged PT and PTTDecreased fibrinogenDecreased plateletsIncreased fibrin degradation products and D-dimersPresence of helmet cells, schistocytesIncreased PF4 (platelet factor 4)Increased FPA (fibrinopeptide A)Decreased factor V, VIII, XIII

**Treatment**

Treatment of underlying disorderReplacement therapy of components as indicated

Neoplastic Disorders {#Sec56}
====================

Acute Leukemia {#Sec57}
--------------

**Epidemiology (Table ** [2](#Tab2){ref-type="table"} **)**

Table 2Prevalence of leukemiaTypePrevalence (%)Acute lymphoblastic*75*--*80*• Pre B cell*80*• Mature B cell (Burkitt)*1*--*2*• T cell*15*--*20*Acute myeloblastic*20 %*Acute undifferentiated*\< 0.5 * *%*Acute mixed lineageChronic Myeloid• Philadelphia chromosome positive• Juvenile myelomonocytic*3 %*

*25--30 % of all childhood cancer*Peak age 2--5 years

**Clinical presentation**

AnorexiaFatigueFeverBone and joint pain (especially lower extremities)PallorPetechiae, ecchymoses, epistaxisExtramedullary spreadLymphadenopathyHepatosplenomegalyCough, orthopneaCNS disease---5 %---cranial nerve palsiesTesticular involvement---20 %---testicular enlargementOvarian involvement---30 %Skin lesionsGingival hypertrophy

**Laboratory**

CytopeniasThrombocytopenia---90 %Anemia---80 %Neutropenia95 % have two cytopenias4 % have only one cytopenia1 % have a normal CBC50 % with elevated WBCUsually see blasts if WBC \> 5000Flow cytometry diagnosis

**Peripheral blood**

ALL: Peripheral blood usually shows leukocytosis with a population of large mononuclear cells (Fig. [12](#Fig12){ref-type="fig"})Fig. 12Peripheral blood showing leukocytosis with a population of large mononuclear cells with high nuclear-cytoplasmic ratio, scant *blue* cytoplasm, and fine chromatin with occasional nucleoli. These are features of lymphoblasts. Note scattered smudge cells, another feature often seen in peripheral smears with leukemiaAML: Peripheral blood usually shows myeloblasts with a high ratio of nucleus to cytoplasm (Fig. [13](#Fig13){ref-type="fig"})Fig. 13Peripheral blood showing two myeloblasts with a high ratio of nucleus to cytoplasm, finely dispersed chromatin and one or more large nucleoli (*arrows*). Acute myeloid leukemia represents only 20 % of childhood leukemia

**Treatment**

Per local or national protocols

**Associated syndromes/risk factors**

ALLDown's syndrome.◦ Acute leukemia is 34 times more common in children with Down's syndrome.◦ 20--30 % will develop leukemia by age 3 years.◦ Ratio of ALL and AML is the same as the general population.◦ AML has a better outcomes in children with Down's syndrome.◦ 10 % of neonates with Down's syndrome may develop a transient leukemia or myelodysplastic syndrome.▪ Characterized by a high leukocyte count, blast cells, anemia , thrombocytopenia and hepatosplenomegaly.▪ Resolve within days to weeks from initial presentation.Ataxia-telangiectasia.Bloom's syndrome.◦ Immunodeficiency, progeria, growth retardation.◦ Chromosome fragility/breakage.◦ Predisposition to cancer.Fanconi anemia.◦ Pancytopenia, radial bone abnormalities, kidney, skin, or GI abnormalities .◦ Chromosome fragility/breakage.AMLIonizing radiationOrganic solventsParoxysmal nocturnal hemoglobinuriaDown's syndromeFanconi anemiaBloom's syndromeKostmann syndrome◦ Severe congenital neutropenia◦ High mortality rate---70 %Shwachman--Diamond syndrome◦ Congenital neutropenia◦ Metaphyseal chondrodysplasia◦ Exocrine pancreatic deficiencyDiamond--Blackfan syndrome◦ Congenital pure red cell aplasia◦ Increased erythrocyte adenosine deaminase◦ Short stature◦ Developmental delay◦ Thumb malformations◦ Craniofacial anomalies◦ Urogenital anomalies◦ Increased MCV on CBCNeurofibromatosis◦ Bone marrow failure◦ Predisposition to cancers, especially AML and neuroblastomaChronic myelogenous leukemia (CML)99 % characterized by specific translocation known as the Philadelphia chromosome t(9;22)

Lymphadenopathy {#Sec58}
===============

**Causes of lymphadenopathy according to location**

CervicalOropharyngeal infections, for example, EBVMycobacterial lymphadenitisCat scratch diseaseKawasaki diseaseSupraclavicularRight side---Malignancy or infection in the mediastinumLeft side---Malignancy or infection from the abdomenLymphomaTuberculosisHilarTuberculosisHistoplasmosisLeukemiaLymphomaSarcoidosisAxillaryCat scratch diseaseArm or chest infectionLeukemiaLymphomaAbdominalMalignancyMesenteric adenitis

**Clinical approach to lymphadenopathy**

HistoryAssociated other systemic symptomsAgeLymph node enlargement in children less than 5 years most likely infectiousHistiocytosis can cause lymphadenopathy in children \< 3 yearsLarge lymph node in neonate most likely related to congenital infectionLikelihood of malignant lymphoma increases in adolescentsLocationSupraclavicular lymphadenopathy is always abnormal and the chances of malignancy are highSizeSize of the enlarged lymph node aids in determining the need for further evaluationAxillary and cervical \> 1 cmInguinal \> 1.5 cmEpitrochlear \> 0.5 cmAnywhere \> 2 cmCharacteristicsUsually develops over weeks or months.Nontender, discrete, firm, rubbery, often immobile

**Biopsy criteria**

Size\> 2 cmIncreasing over 2 weeksNo decrease in size after 4 weeksLocationSupraclavicularConsistencyHardMattedRubberyAssociated featuresAbnormal CXRFeverWeight lossHepatosplenomegaly

Hodgkin Lymphoma {#Sec59}
================

**Hodgkin disease (HD)**

Rare in children \< 10 years15 % of cancers in persons between 15 and 19 yearsBimodal peaks of incidence from 15--35 years of age and at 55 years of ageInfectious agents may be involvedEBVHHV6CMVReed--Sternberg cell is the hallmark of HD (Fig. [14](#Fig14){ref-type="fig"})Fig. 14Hodgkin's lymphoma presents as a localized or regional lymphadenopathy. The characteristic cell in Hodgkin's is the Reed--Sternberg cell (*arrow*)

**Clinical presentation**

Painless lymphadenopathyAirway obstructionPleural dysfunctionPericardial dysfunctionHepatocellular dysfunctionBone marrow infiltrationSystemic symptoms (B symptoms)Fever \> 39  CWeight loss \> 10 % of body weightNight sweats

**Diagnosis**

CXRCT abdomen and pelvisPET scanCBC, CMP, ESR, ferritin

**Treatment**

Chemotherapy and radiotherapy are very effectiveChemotherapy regimensCOPP (cyclophosphamide, vincristine, procarbazine, and prednisone)ABVD (Doxorubicin (adriamycin) bleomycin, vinblastine, and dacarbazine)

**Prognosis**

Early stage disease have event free survival 85--90 %, overall survival at 5 years of 95 %Poor prognostic featuresBulky tumorAdvanced stage at diagnosisB symptomsPatient who relapse \> 12 months after chemotherapy alone or combined modality have good retrieval response

Non-Hodgkin Lymphoma {#Sec60}
====================

60 % of all lymphomas in childrenBurkitt lymphoma is the most commonMost children have de novo disease (no underlying condition)Related diseasesSevere combined immunodeficiency (SCID)Wiskott--Aldrich syndromeAtaxia telangiectasiaBloom's syndromeHIVEBV

**Clinical presentation**

Rapidly growing tumors with symptoms based on size and locationBurkitt lymphoma of abdomen (sporadic type) more common in the USABurkitt lymphoma of head and neck (endemic type) more common in AfricaSuperior vena cava (SVC) syndrome---chest involvementIntestinal obstruction---abdominal massParaplegia with spinal cord involvementTumor lysis syndromeHyperkalemia, hyperuricemia, hyperphosphatemia, hypocalcemia

**Diagnosis**

CXRCT abdomen and pelvisCBC, CMP, Mg, Phos, Uric Acid, LDHEBV

**Biopsy**

Classic "starry sky" appearance of Burkitt lymphoma (Fig. [15](#Fig15){ref-type="fig"})Fig. 15Classic "starry sky" appearance of Burkitt lymphoma. The stars are actually macrophages that are phagocytosing apoptotic Burkitt cells. This example presented as a colonic mass with intussusception

Fig. 16Medulloblastoma (40x) is a so-called "small round blue" cell tumor of childhood. Medulloblastoma is a posterior fossa tumor and the second most common brain tumor of childhood

Fig. 17Pilocytic astrocytoma is composed of bipolar cells with frequent microcystic spaces. Juvenile pilocytic astrocytoma is the most common childhood primary brain tumor

Fig. 18Neuroblastoma is one of the small round blue cell tumors of childhood. A majority are at least poorly differentiated with the presence of some neuropil (black arrow) often in association with Homer- Wright rosettes (10x)

Fig. 19Wilms' Tumor is a triphasic tumor composed of blastemal (black arrow), epithelial (arrowhead) and mesenchymal components (red arrow). Most are diagnosed before 6 years of age

Fig. 20At low power (10x) alveolar rhabdomyosarcoma has a vaguely alveolar growth pattern with neoplastic cells lining thin fibrous septae. At higher power pink cytoplasmic material is evident (arrows) showing early myogenic differentiation

Fig. 21Osteosarcoma is composed of a pleomorphic cell population of ovoid and frankly bizarre cells with focal osteoid formation (black arrow)

Fig. 22Left -- Gross photo showing the white tumor mass filling twothirds of the posterior chamber of the eye. Right -- Retinoblastoma is another "small round blue" cell tumor of childhood

Fig. 23Hepatoblastoma is composed of epithelial components -- fetal, embryonal, or a mixture of the two -- and occasionally mesenchymal components. The image here is of fetal epithelial type hepatoblastoma with a classic "light and dark" appearance

**Treatment**

Chemotherapy

**Prognosis**

Excellent in most of children90--100 % survival rate with localized disease

Brain Tumors {#Sec61}
============

**Epidemiology**

Almost 20 % of all pediatric cancersPeak age 0--4 yearsMost common cancer mortality in children25 % of all deaths from cancer

**Clinical presentation**

Based on location, size, growth rate and ageIncreased intracranial pressureHeadacheVomiting (often mornings)Mental changes, irritabilityVisual disturbances◦ Diplopia◦ Papilledema◦ Parinaud'sGait disturbancesFailure to thriveCranial nerve abnormalitiesFocal neurologic deficitsSeizures

**Pathologic diagnosis**

Based on cell of originCan occur at multiple locations in the CNSInfratentorial---60 %Supratentorial---40 %Common in childrenAstrocytoma (Fig. [17](#Fig17){ref-type="fig"})◦ 40 % of all CNS tumors◦ Juvenile pilocytic astrocytoma---most common subtype in children◦ Classic site for JPA is cerebellum, but can occur anywhere in CNSTreatment◦ Surgery---primary treatment◦ Chemotherapy◦ Radiation therapyMedulloblastoma (Fig. [16](#Fig16){ref-type="fig"})◦ 20 % of all brain tumors (second most common)◦ 90 % of embryonal tumors◦ Arises in cerebellum and fourth ventricle◦ May metastasize down spinal cord and rarely outside CNS◦ Similar cell type to primitive neuroectodermal tumor (PNET)Treatment▪ Surgery---prognosis based on extent of resection▪ Chemotherapy▪ Radiation therapyEpendymoma◦ Derived from the ependymal lining of the ventricles◦ 70 % occur in the posterior fossaPineal tumors◦ Germ cell tumors▪ Germinoma▪ Yolk sac tumor▪ Mixed germ cell tumor◦ Pineoblastoma◦ PNETCraniopharyngioma◦ 7--10 % of childhood brain tumors▪ Suprasellar location◦ Solid and cystic components◦ Associated with panhypopitutarism and visual loss▪ Tumor related▪ Treatment relatedSyndromes associated with brain tumors*Neurofibromatosis type 1:* optic glioma, astrocytoma, neurofibroma, malignant nerve sheath tumor*NF type 2:* vestibular schwannomas, meningiomas, spinal cord ependymoma, spinal cord astrocytoma*Von Hippel--Lindau*: Hemangioblastoma, angiomatosis, pheochromocytoma, renal cell carcinoma, pancreatic cyst*Li--Fraumeni:* astrocytoma*Cowden syndrome:* multiple hamartomas including the brain; dysplastic gangliocytoma of the cerebellum*Turcot syndrome:* medulloblastoma and colon polyps

Neuroblastoma (Fig. [18](#Fig18){ref-type="fig"}) {#Sec62}
=================================================

**Epidemiology**

Third most common pediatric cancer8 % of childhood malignancyMost commonly diagnosed neoplasm in infants (28--39 % of neonatal malignancies)Mean age is 2 years

**Clinical presentation**

Fever, failure to thriveParaneoplastic symptomsSecretory diarrheaIncreased sweatingHypertensionOpsoclonus, myoclonus (dancing eyes and dancing feet)Most cases arise in abdomenAbdominal painDistended abdomen, massThoracic tumorsOccasional Horner's syndromeSpinal tumorsParaplegiasMetastatic diseaseBone pain (bone mets)Cytopenias (bone marrow infiltrate)Orbital proptosis and ecchymosis-"raccoon eyes" (retro-orbital soft tissue infiltrate)Bluish subcutaneous nodules (skin infiltrate)

**Diagnosis**

CT/MRI scans often show calcificationsTumor markersUrine homovanillic acid (HVA), vanillylmandelic acid (VMA)*Poor prognostic factors on pathology*N-myc proto-oncogene (MYCN) amplificationDNA hyperdiploidy (if less than 1 year of age)

**Treatment**

ChemotherapyRadiation therapyStem cell transplantNew vaccines/antibodiesRetinoic acid

**Associated syndromes/risk factors**

Hirschsprung's diseasePheochromocytoma in familyFetal hydantoin syndromeFetal alcohol syndromeNesidioblastosis

Wilms Tumor (Fig. [19](#Fig19){ref-type="fig"}) {#Sec63}
===============================================

*WT-1* gene located on 11p13

**Epidemiology**

Peak incidence 2--5 years of age8 cases/million children \< 15 years

**Clinical presentation**

Abdominal mass often noted first by parentsAbdominal pain, vomiting, hematuria in 12--25 %HypertensionAnomalies and syndromes associated with Wilms tumorBeckwith-Wiedemann (organomegaly, macroglossia, omphalocele, hemihypertrophy)WAGR (aniridia, genitourinary abnormalities, intellectual disability (ID), del 11p13)Denys-Drash (early onset renal failure with renal mesangial sclerosis, male pseudohermaphroditism)

**Diagnosis**

US, KUB, CT, and/or MRIU/A

**Treatment**

Surgery, chemotherapy, and radiotherapyPoor prognostic factorLarge tumor \> 500 gAdvanced stage (III or IV)Unfavorable histologic type

Rhabdomyosarcoma {#Sec64}
================

**Epidemiology**

Most common soft tissue sarcoma3.5 % of childhood tumorsIncreased frequency with neurofibromatosisPeak incidence 1--5 years10 % occur in the first year of life70 % appear within first decade

**Clinical presentation**

Anatomic distributionHead and neck---40 %GU---20 %Trunk---10 %Retroperitoneal and others

**Specific histologic types**

*Embryonal:* 60 %, intermediate prognosis*Alveolar type:* 15 %, most in trunk and extremeties, poor prognosis (Fig. [20](#Fig20){ref-type="fig"})*Botryoid type:* 6 %, "bunch of grapes", most in vagina, uterus, bladder, nasopharynx, and middle ear, good prognosis*Pleomorphic form:* 1 %, adult type

Osteosarcoma {#Sec65}
============

**Epidemiology**

Most common primary malignant bone tumor in childrenMost present in second decadeMore common in males

**Clinical presentation**

Local pain, swelling, often history of injuryAssociated syndromes/risk factorsRetinoblastoma , Li--Fraumeni syndrome, Paget disease, radiotherapy

**Diagnosis**

Pathologic findings (Fig. [21](#Fig21){ref-type="fig"})Spindle to epithelioid cells producing osteoid (bone forming)Radiologic findingsScelerotic destruction (sunburst)Lytic lesion less common

**Differential diagnosis**

Ewing sarcomaOsteomyelitis

**Metastasis**

Lung and bone

**Treatment**

ChemotherapySurgical resectionAmputationProsthesis

Ewing Sarcoma {#Sec66}
=============

**Epidemiology**

Second decadeMore common in males

**Clinical presentation**

Local pain, swelling, feverLocationDiaphysis of long bone, flat bones

**Diagnosis**

PathologyUndifferentiated small round cell tumorRadiologic findingsPrimarily lytic lesions (onion ring appearance)

**Treatment**

ChemotherapyRadiation therapy+/ − surgery

**Prognosis**

Localized---60 % survivalMetastatic---20--30 % survival

Osteoid Osteoma {#Sec67}
===============

Small benign bone tumor

**Epidemiology**

Occurs in patients from 2--50 years of ageMale are more common than females

**Clinical presentation**

Gradually increasing painOften worse at night and relieved by aspirinLower extremity lesion may develop limp, atrophy, or weaknessPalpation and range of motion may not alter the discomfortVertebral lesions may cause scoliosisMost common in proximal tibia and femur, can involve any bone

**Diagnosis**

Radiologic findingsRound, oval metaphyseal or diaphyseal lucency surrounded by sclerotic boneCentral lucency or nidus shows intense uptake of bone scan25 % only visualized by CTNot seen on MRI

**Treatment**

Removal of the lesion and ablation of nidusTreat pain with aspirin

Retinoblastoma {#Sec68}
==============

**Epidemiology**

Arises following mutation of both Rb genes at 13q14Hereditary form associated with germline inactivating mutation of one copy of RB1 geneNeed "second hit", somatic mutation to second RB1 gene to develop tumor80--90 % with germline mutation get a second hit and develop retinoblastomaSporadic cases involve 2 somatic mutations to RB1 gene60 % sporadic, 40 % familial30 % bilateral90 % of familial tumors are bilateralMay be present congenitallyMost present between 6 months and 2 years of age

**Clinical presentation**

Leukocoria---white pupillary reflex*Strabismus* ***---***usually the initial presenting complaintOrbital inflammation, proptosis, hyphema , irregular pupils with advanced diseasePain if secondary glaucoma develops

**Diagnosis**

Exam by ophthalmologist under anesthesiaCT or MRIMetastatic workup for larger lesions

**Treatment**

ChemotherapyFocal laser photocoagulationRadiation therapy in severe casesEnucleation of unresponsive cases, especially if loss of vision (Fig. [22](#Fig22){ref-type="fig"})

**Prognosis**

95 % cure rate in US

Hepatoblastoma (Fig. [23](#Fig23){ref-type="fig"}) {#Sec69}
==================================================

**Epidemiology**

Children \< 3 yearsCan be congenital90 % occur by age of 5 years, 70 % by age of 2 yearsMale predominancePrevalence of 1 per 120,000 (1 per 1 million children under age 15 years)Associated syndromes/risk factorsFamilial adenomatous polyposis (APC gene mutation)Glycogen storage diseaseBeckwith--Wiedemann syndromeLi--Fraumeni syndromeLow birth weight infantsWilms tumor

**Clinical presentation**

Large asymptomatic massRight lobe more commonWeight loss, anorexia, vomiting, or abdominal pain

**Diagnosis**

US, KUB, CT, and/or MRIBilirubin and liver enzymes are usually normalAlpha-fetoprotein is elevated in all hepatoblastomasAnemia and thrombocytosis are commonHepatitis B and C serologies {usually negative}

**Treatment**

ChemotherapyTumor resectionAs much as 85 % of liver can be resectedHepatic regeneration noted within 3--4 months of surgery
